- Home
- TLRY vs CSTL Comparison
TLRY vs CSTL Comparison
Compare TLRY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- CSTL
- Stock Information
- Founded
- TLRY N/A
- CSTL 2007
- Country
- TLRY Canada
- CSTL United States
- Employees
- TLRY N/A
- CSTL 784
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- CSTL Medical Specialities
- Sector
- TLRY Health Care
- CSTL Health Care
- Exchange
- TLRY Nasdaq
- CSTL Nasdaq
- Market Cap
- TLRY 502.9M
- CSTL 456.2M
- IPO Year
- TLRY 2018
- CSTL 2019
- Fundamental
- Price
- TLRY $0.43
- CSTL $15.95
- Analyst Decision
- TLRY Hold
- CSTL Strong Buy
- Analyst Count
- TLRY 3
- CSTL 6
- Target Price
- TLRY $1.38
- CSTL $37.67
- AVG Volume (30 Days)
- TLRY 21.1M
- CSTL 527.3K
- Earning Date
- TLRY 07-28-2025
- CSTL 05-05-2025
- Dividend Yield
- TLRY N/A
- CSTL N/A
- EPS Growth
- TLRY N/A
- CSTL N/A
- EPS
- TLRY N/A
- CSTL N/A
- Revenue
- TLRY $826,656,000.00
- CSTL $347,083,000.00
- Revenue This Year
- TLRY $9.81
- CSTL N/A
- Revenue Next Year
- TLRY $5.78
- CSTL $1.80
- P/E Ratio
- TLRY N/A
- CSTL N/A
- Revenue Growth
- TLRY 11.22
- CSTL 38.43
- 52 Week Low
- TLRY $0.41
- CSTL $15.45
- 52 Week High
- TLRY $2.15
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- TLRY 41.30
- CSTL 33.63
- Support Level
- TLRY $0.42
- CSTL $15.45
- Resistance Level
- TLRY $0.50
- CSTL $16.43
- Average True Range (ATR)
- TLRY 0.03
- CSTL 0.59
- MACD
- TLRY 0.00
- CSTL 0.04
- Stochastic Oscillator
- TLRY 7.13
- CSTL 15.93
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.